PROSTATIC HYPERPLASIA;

Abstract

Lower Urinary Tract Symptoms. Alpha-1 adrenoceptor antagonists are mostfrequently prescribed medical management for LUTS and among these tamsulosin andterazosin are the most common. Objectives: To access comparison of efficacy of tamsulosinand terazosin for management of LUTS due to prostatic hyperplasia in terms of InternationalProstate Symptom Score (IPSS). Place and duration: Study being conducted at Departmentof Urology and Kidney Transplantation, Allied Hospital, Faisalabad for period of 24 months from01-07-2014 to 30-06-2016. Methodology: 659 male patients enrolled in study and randomlyassigned to Group A (Patients being administered with tamsulosin) and Group B (Patients beingadministered with terazosin) and improvement in IPSS monitored over period of two weeks.Results: 659 patients enrolled with mean age+sd as 61.9+10.2 years. Group A includes 330patients while Group B include 329 patients. Among Group A, 250 patients showed significantimprovement in IPSS while in Group B, 215 patients showed significant response to medicalmanagement in terms of IPSS and both groups showed statistically comparative response.Statistical response of management also determined in terms of variables of IPSS severity,prostatic size and age of patient and found that efficacy of the two groups were statisticallycomparable for patients with mild IPSS while in patients with moderate IPSS has response totreatment with tamsulosin but no statistical association of efficacy for treatment with terazosin.No statistical response was found for improvement in symptoms in cases with severe IPSS ineither groups. When response monitored in terms of prostate size in both groups, it was foundthat both groups have statistical response when prostate size is less than 35 grams, between35-55 grams but in case when prostate size was more than 55 grams, no statistical responsewas found with group B patients. When response was measured in terms of variable of age,results were consistent with the fact that statistically significant response of efficacy was foundin either groups for age group 45-55 years and 56-65 years but no statistical response wasfound for Group B when considered for age group more than 65 years. Conclusion: Based onresults it is concluded that both tamsulosin and terazosin has got comparative results in overallresponse. However, tamsulosin has superiority in treatment when IPSS is moderate, prostatesize is more than 55 grams and age of patient is more than 65 years.